台灣臨床試驗主持人資料庫|TPIDB

2016-05-01 - 2020-04-30

Phase III

A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)

Condition/Disease

Advanced Hepatocellular Carcinoma
Test Drug

Pembrolizumab (MK-3475) /KEYTRUDA

Participate Sites
7Sites

Terminated6Sites

邱昌芳

China Medical University Hospital-Taipei

未分科

林錫銘

Linkou Chang Gung Medical Foundation

Digestive System Department

2015-04-01 - 2018-12-31

Phase III

a double-blind, randomized, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of lacosamide as adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures in subjects with idiopathic generalized epilepsy

Condition/Disease

idiopathic generalized epilepsy
Test Drug

VIMPAT® Lacosamide

Participate Sites
3Sites

Terminated2Sites

周宜卿

China Medical University Hospital-Taipei

未分科

2015-09-09 - 2017-11-30

Phase III

TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients with Mutant EGFR Non-small Cell Lung Cancer (NSCLC) after Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinumdoublet Chemotherapy

Condition/Disease

Non-Small Cell Lung Cancer (NSCLC)
Test Drug

CO-1686 Hydrobromide Film-Coated Tablet

Participate Sites
6Sites

Terminated5Sites

夏德椿

China Medical University Hospital-Taipei

未分科

陳育民

Taipei Veterans General Hospital

Division of Thoracic Medicine

2016-02-01 - 2019-12-31

Phase III

PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS (AXSPA) WITHOUT X-RAY EVIDENCE OF ANKYLOSING SPONDYLITIS (AS) AND OBJECTIVE SIGNS OF INFLAMMATION

Condition/Disease

Active axial spondyloarthritis (axSpA)
Test Drug

Certolizumab Pegol 200mg/ml, solution for subcutaneous injection

Participate Sites
5Sites

Terminated4Sites

黃春明

China Medical University Hospital-Taipei

未分科

2017-03-14 - 2020-11-01

Phase III

A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer

Condition/Disease

ALK-positive advanced lung cancer
Test Drug

Brigatinib (AP26113)

Participate Sites
6Sites

Recruiting5Sites

夏德椿

China Medical University Hospital-Taipei

未分科

陳育民

Taipei Veterans General Hospital

Division of Thoracic Medicine

2018-01-01 - 2020-12-31

Phase II

A Phase 2a, Open-Label, Study Evaluating the Safety and Anti-Viral Activity of ARB-001467 in Non-Cirrhotic, HBeAg-Negative Subjects with Chronic HBV Infection (Genotype A or B) in Combination with PEG-IFN α-2a and Tenofovir Disoproxil Fumarate

Condition/Disease

Chronic HBV Infection (Genotype A or B)
Test Drug

ARB-001467 Injection (2 mg/mL)

Participate Sites
6Sites

Terminated4Sites

彭成元

China Medical University Hospital-Taipei

未分科

林俊彥

Linkou Chang Gung Medical Foundation

Digestive System Department

2018-07-01 - 2020-06-30

Phase III

A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment

Condition/Disease

Pancreatic Cancer
Test Drug

EndoTAG-1

Participate Sites
12Sites

Terminated11Sites

白禮源

China Medical University Hospital-Taipei

未分科

陳仁熙

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-09-01 - 2022-05-25

Phase III

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 2

Condition/Disease

Moderately to Severely Active Ulcerative Colitis
Test Drug

Mirikizumab

Participate Sites
12Sites

Recruiting10Sites

Terminated1Sites

周仁偉

China Medical University Hospital-Taipei

未分科

2019-01-24 - 2020-12-31

Phase III

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

Condition/Disease

Breast Cancer
Test Drug

DS-8201a

Participate Sites
6Sites

Recruiting5Sites

劉良智

China Medical University Hospital-Taipei

未分科

曾令民

Taipei Veterans General Hospital

Division of General Surgery

2017-04-18 - 2020-02-01

Phase II

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Condition/Disease

Cholangiocarcinoma
Test Drug

INCB054828

Participate Sites
5Sites

Terminated4Sites

白禮源

China Medical University Hospital-Taipei

未分科

Search Result

List